. 2016 Aug 27;16(1):129. doi: 10.1186/s12890-016-0289-y

Table 1.

Characteristics of the included studies

Study	Study design	Settings	Sample size (NIV/IMV)	Cause of immunodeficiency	SAPS II (SD orrange)	Number of NIV patients that switched to IMV (%)	Outcomes
Azoulay 2001	Cohort, single-centered	France, ICU	96 (48/48)	Hematologic malignancy or solid tumors	NIV: 47 (38–60)	Not specified	1. 30-day mortality
Azoulay 2001	Cohort, single-centered	France, ICU	96 (48/48)	Hematologic malignancy or solid tumors	IMV: 44.5 (36–59)	Not specified	2. Nosocomial infections
Azoulay 2003	Case-control, single-centered	France, ICU	15 (7/8)	Hematological malignancy	NS	4 (57.1)	1. Mortality (in ICU)
Azoulay 2004	Case-control, single-centered	France, ICU	148 (79/69)	Hematological malignancy, allogeneic BMT, solid tumors, chemotherapy	NS	45 (57.0)	1. Mortality (in hospital)
B-M 2013	Case-control, single-centered	Spain, ICU	41 (35/6)	Hematological malignancy	63 (18)	14 (40.0)	1. Mortality (in hospital)
							2. Mortality (in ICU)
							3. Duration of ICU stay
							4. Duration of hospitalization
							5. Nosocomial infections
							6. Duration of mechanical ventilation
Confalonieri 2002	Cohort, single-centered	Italy, ICU	48 (24/24)	AIDS	NIV: 37 (9)	8 (33.0)	1. Mortality (in ICU)
					IMV: 38 (5)		2. Duration of ICU stay
							3. Duration of hospitalization
							4. Nosocomial infections
							5. Duration of mechanical ventilation
Depuydt 2004	Cohort, single-centered	Belgium, ICU	78 (26/52)	Hematological malignancy and allogeneic BMT	NIV: 46	18 (69.2)	1. Mortality (in hospital)
Depuydt 2004	Cohort, single-centered	Belgium, ICU	78 (26/52)	Hematological malignancy and allogeneic BMT	IMV: 46	18 (69.2)	1. Mortality (in hospital)
Depuydt 2010	Cohort, single-centered	Belgium, ICU and general medical units	91 (24/67)	Hematological malignancy and allogeneic BMT	NIV: 52 (15)	18 (75.0)	1. Mortality (in ICU)
					IMV: 65 (18)		2. Mortality (in hospital)
					IMV: 65 (18)		3. Duration of ICU stay
Gachot 1992	Case-control, single-centered	France, ICU	45 (36/9)	AIDS	NS	11 (30.6)	1. Mortality (in ICU)
Gachot 1992	Case-control, single-centered	France, ICU	45 (36/9)	AIDS	NS	11 (30.6)	2. Mortality (in hospital)
Gristina 2011	Case-control, multicenter	Italy, ICU	1302 (274/1028)	Hematologic malignancy	NIV: 49 (16)	126 (46.0)	1. Mortality (in ICU)
					IMV: 58 (18)		2. Mortality (in hospital)
							3. Duration of ICU stay
							4. Duration of hospitalization
							5. Duration of mechanical ventilation
							6. Nosocomial infections
Molina 2012	Case-control, multicenter	Spain, ICU	300 (131/169)	Hematological malignancy and BMT	NS	79 (60.3)	1. Mortality (in ICU)
Pancera 2008	Case-control, single-centered	Italy, PICU	239 (120/119)	Hematologic malignancy or solid tumors	NS	31 (25.8)	1. Mortality (in ICU)
Pancera 2008	Case-control, single-centered	Italy, PICU	239 (120/119)	Hematologic malignancy or solid tumors	NS	31 (25.8)	2. 30-day mortality
Rabitsch 2005	Case-control, single-centered	Austria, ICU	82 (35/47)	Autologous or allogeneic BMT for hematological malignancies	NIV: 62 (49–84)	24 (68.6)	1. Mortality (in hospital)
Rabitsch 2005	Case-control, single-centered	Austria, ICU	82 (35/47)	Autologous or allogeneic BMT for hematological malignancies	IMV: 68 (51–87)	24 (68.6)	1. Mortality (in hospital)
Turkoglu 2013	Case-control, single-centered	Turkey, ICU	67 (46/21)	Hematological malignancies	NS	36 (78.3)	1. Mortality (in ICU)

Abbreviations: AIDS acquired immune deficiency syndrome; BMT bone marrow transplantation; ICU Intensive Care Unit; PICU Pediatric Intensive Care Unit; USA United States of America; NIV Noninvasive mechanical ventilation; IMV Invasive mechanical ventilation; SAPS II Simplified Acute Physiologic Score II; NS Not stated; SD Standard deviation